News | Brachytherapy Systems | December 29, 2020

Brachytherapy Planning and a Speed Revolution in Proton Monte Carlo Dose Computation

RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.

December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.

In line with the company’s aim of integrating with as many treatment delivery systems as possible, the new release includes support for high-dose-rate (HDR) brachytherapy planning. RayStation 10B features automatic channel reconstruction in combination with powerful dwell-time optimization, enabling faster and more consistent creation of high-quality brachytherapy plans. The efficiency and possibilities of brachytherapy planning are further enhanced by tools for working with multiple image sets, image deformation and dose summation. 

HDR brachytherapy is a radiation therapy technique in which a small radioactive source is placed at different positions inside the patient to obtain an advantageous dose distribution. High doses can be delivered to tumors while sparing organs at risk. The technique is used, for example, to treat gynecological, prostate, breast, head-and-neck and skin cancers.

Another notable addition in RayStation 10B is the multi-GPU Monte Carlo dose engine for proton planning. With typical final dose computation times of less than five seconds, the GPU Monte Carlo algorithm is expected to revolutionize planning workflows at proton clinics. The physics algorithms of the GPU proton Monte Carlo dose engine are identical to those in the now well-established RayStation CPU proton Monte Carlo dose engine, and dosimetric results are equally strong.

Machine-learning capabilities were introduced in RayStation 8B and are being continuously improved with each successive release. In RayStation 10B, machine learning applications further increase efficiency and improve consistency for photon and robust proton planning, and deep-learning organ segmentation. 

The robust optimization framework has been extended to take intra- and inter-fractional motion into account, with consideration for motion during the delivery of single fractions and changes over the entire treatment course. This framework supports improved plan quality, for example in cases with organ motion. 10B also introduces machine parameter improvements to utilize the full potential of the most common linacs. As a result, it is now possible to create treatment plans with more conformal dose distribution and lower dose to organs at risk.

Other enhancements include closer integration with the oncology information system RayCare. When running RayStation in a RayCare environment, the planning task list is now accessible in RayStation for improved workflow management.

Johan Löf, CEO of RaySearch, said: “Each release of RayStation takes clinical workflows to the next level. Brachytherapy is a highly accurate technique, and the capabilities of our advanced software will bring a new dimension to the treatment of several cancer types.”

For more information: www.raysearchlabs.com

Related Content

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

News | Linear Accelerators | January 20, 2021
January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and...
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) ann
C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.
News | Proton Therapy | December 28, 2020
December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in...
A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

News | Nuclear Imaging | December 22, 2020
December 22, 2020 — Researchers in the DO...